NCM
CCCC icon

Nantahala Capital Management’s C4 Therapeutics CCCC Stock Holding History

Nantahala Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000,000
Closed -$1.86M – 131
2023
Q3 		$1.86M Hold
1,000,000
– – 0.16% 91
2023
Q2 		$2.75M Buy
+1,000,000
New +$3.21M 0.27% 72

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nantahala Capital Management's CCCC Position: Q4 2023 in Review

Nantahala Capital Management sold out of C4 Therapeutics (CCCC) in Q4 2023, closing a stake of 1,000,000 shares — an estimated $1.86M sold.

Nantahala Capital Management first reported a position in CCCC in Q2 2023 and held it in 2 quarters. The position peaked at $2.75M in Q2 2023. 92 funds tracked by Wall St. Rank hold CCCC as of Q4 2023.

  • Nantahala Capital Management reported no remaining C4 Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Nantahala Capital Management sold 1,000,000 C4 Therapeutics shares in Q4 2023, an estimated $1.86M.
  • Nantahala Capital Management first reported a position in C4 Therapeutics in Q2 2023 and held it in 2 quarters.
  • Nantahala Capital Management's C4 Therapeutics position peaked at $2.75M in Q2 2023.
  • 92 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2023.

Based on Nantahala Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.